Addressing insulin resistance may help lower dementia risk, but researchers have not proved that it does. No trial has shown that treating insulin resistance itself reduces new dementia cases, according to a 2025 JAMA Neurology meta-analysis. Insulin resistance means the body's cells respond less effectively to insulin, which helps regulate blood sugar. The evidence gives people good reason to monitor metabolic health, but not to treat insulin resistance as a proven dementia-prevention target.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why does insulin resistance raise concern?
- What happened in prevention trials?
- Do glucose-lowering medications reduce risk?
- What does the evidence mean for you?
- Questions to take to a clinician
Why does insulin resistance raise concern?
Diabetes has a consistent association with dementia. A meta-analysis of 28 prospective studies found that people with diabetes had 73% higher all-cause dementia risk, 56% higher Alzheimer's risk, and 127% higher vascular-dementia risk than people without diabetes, according to the Journal of Diabetes Investigation. These are group-level associations, not predictions for individuals. The studies also do not show that treating insulin resistance reverses the added risk.
A Finnish cohort of 3,695 adults offers a more specific clue. Higher fasting insulin and HOMA-IR, a measure of insulin resistance, predicted poorer and faster-declining verbal fluency over 11 years. They did not predict poorer word-list learning or delayed recall. That selective pattern matters. Insulin resistance may mark or contribute to certain cognitive risks, but the study cannot establish that lowering it prevents dementia.
What happened in prevention trials?
The Diabetes Prevention Program Outcomes Study tested lifestyle intervention and metformin against placebo. Both interventions reduced progression to type 2 diabetes, but neither produced better cognition 12 to 14 years after randomization. Higher HbA1c, a measure of average blood sugar, was associated with worse cognition in the Diabetes Care study. Look AHEAD produced a similar caution.
The randomized trial followed 3,802 overweight or obese adults with type 2 diabetes. About 10 years of weight-loss and physical-activity intervention did not reduce overall mild cognitive impairment or probable dementia compared with diabetes education, according to the Neurology report. These findings do not prove that metabolic health is irrelevant to the brain. They show that success with weight, activity, blood sugar, or diabetes prevention cannot automatically be translated into demonstrated dementia prevention.
Do glucose-lowering medications reduce risk?
The 2025 JAMA Neurology analysis combined 23 placebo-controlled glucose-lowering trials. Overall, treatment did not significantly reduce dementia or cognitive impairment. The odds ratio was 0.83, with a 95% confidence interval from 0.60 to 1.14. The trials recorded few dementia events and lasted an average of only 31.8 months.
Because dementia develops over a long period, those limitations leave open the possibility that a longer study could produce a different result. GLP-1 receptor agonists showed a promising subgroup signal, with an odds ratio of 0.55. SGLT2 inhibitors did not show the same signal, and neither medication class significantly reduced Alzheimer dementia. That is a reason for further research, not a basis for prescribing either class solely to prevent dementia.
What does the evidence mean for you?
The practical meaning depends on why treatment is being considered: The key distinction is between managing a metabolic problem and promising a brain outcome. One may be a valid treatment goal even when the other remains unproven.
- If you have insulin resistance but no cognitive symptoms, these studies cannot calculate how much treating it would change your personal dementia risk.
- If you have diabetes, the association with dementia deserves attention, but association does not reveal how much risk any particular treatment can remove.
- If you are considering a GLP-1 receptor agonist or SGLT2 inhibitor, dementia prevention alone is not supported as a treatment rationale by current trial evidence.
- If you or a family member has cognitive changes, do not assume insulin resistance explains them. The Finnish study found an association with verbal fluency, not with every tested cognitive skill.
Questions to take to a clinician
Ask the clinician to separate the treatment's measurable purpose from any hoped-for effect on dementia: Before changing medication or starting a new plan, write down the intended treatment target and the measure that will show whether it was met.
- What diagnosis or test result are we treating?
- What outcome should improve, and how will we track it?
- Would this treatment still be recommended without a possible dementia benefit?
- Are memory, language, or other cognitive concerns being assessed separately?
- What evidence applies to someone with my health history and risk factors?
